In the first study, published in 2004, HER2 mutations were presented in 10% of the lung adenocarcinomas [238] Subsequently, several studies have reported higher case numbers, with lower frequencies (1.6% testing 671 NSCLC cases) [239]. Here, ERBB2 is linked to non-small cell lung carcinoma.